Table 1 Study characteristics

Hu et al. (2021) [15]

67

52 (28–70)

BRAF/RAS wild type initially unresectable liver-limited mCRC

mFOLFOXIRI + cetuximab

Cetuximab 500 mg/m², oxaliplatin 85 mg/m², irinotecan 165 mg/m², folinic acid 400 mg/m², 5-FU 2800 mg/m² for 46 h every 2 weeks

7 (4–12)

34

55 (29–70)

mFOLFOXIRI

Oxaliplatin 85 mg/m², irinotecan 165 mg/m², folinic acid 400 mg/m², 5-FU 2800 mg/m² for 46 h every 2 weeks

6 (2–12)

Modest et al. (2019) [16]

63

58 (31–76)

RAS wild-type untreated mCRC

mFOLFOXIRI + panitumumab

Panitumumab 6 mg/kg, oxaliplatin 85 mg/m², irinotecan 150 mg/m², folinic acid 200 mg/m², 5-FU 3000 mg/m² for 46 h every 2 weeks

11 (2–12)

33

60 (32–77)

m FOLFOXIRI

Oxaliplatin 85 mg/m², irinotecan 150 mg/m², folinic acid 200 mg/m², 5-FU 3000 mg/m² for 46 h every 2 weeks

11 (2–12)

Assenat et al. (2011) [11]

42

60 (32–76)

Unresectable mCRC

FOLFIRINOX + cetuximab

Cetuximab 400 mg/m², oxaliplatin 85 mg/m², irinotecan 180 mg/m², 5-FU 400 g/m², 5-FU 2800 mg/m² for 46 h every 2 weeks

9 (1–12)

Fornaro et al. (2013) [14]

37

63 (33–72)

Quadruple wild-type (KRAS, NRAS, HRAS, BRAF) mCRC

A slightly modified GONO-FOLFOXIRI + panitumumab

Panitumumab 6 mg/kg, oxaliplatin 85 mg/m², irinotecan 150 mg/m², folinic acid 200 mg/m², 5-FU 2400 mg/m² for 46 h every 2 weeks

11 (3–16)

Garufi et al. (2010) [12]

43

61 (33–75)

Unresectable liver-limited mCRC

Chronomodulated FOLFOXIRI + cetuximab

Cetuximab 400 mg/m²/2 weeks—250 mg/m² weekly; irinotecan 110–130 mg/m², oxaliplatin 15–20 mg/m²/day × 4 days, folinic acid 150 mg/m²/day × 4 days, 5-FU 550–600 mg/m²/d × 4 days every 2 weeks

6 (3–15)

Saridaki et al. (2012) [13]

30

64 (36–70)

KRAS wild-type mCRC

FOLFOXIRI + cetuximab

Cetuximab 500 mg/m², oxaliplatin 65 mg/m², irinotecan 150 mg/m², folinic acid 200 mg/m², 5-FU 400 g/m², 5-FU 1200 mg/m² for 44 h every 2 weeks

/